Table 1.
Comparison of Dex-treated versus untreated GBM tumors using the Nanostring Pan-Cancer Immune panel. FFPE tumors from each group were selected based on comparable number of CD163 positive cells. Of 770 genes on the panel, 542 had average raw counts greater than 50. 71 of these genes have a p-value less than 0.05 and fold change greater than 2. Only 1 of the 71 genes, Complement C7, is up-regulated by Dex-treatment.
Gene Name | Accession # | Fold Change Dex vs No Dex | P value |
---|---|---|---|
Anti-inflammatory | |||
ATF1 | NM_005171.2 | −2.07 | 0.025 |
CSF1 | NM_000757.4 | −3.96 | 0.024 |
CSF1R | NM_005211.2 | −12.64 | 0.010 |
IL13RA1 | NM_001560.2 | −2.04 | 0.044 |
PDCD1LG2 | NM_025239.3 | −22.19 | 0.006 |
SMAD3 | NM_005902.3 | −2.94 | 0.043 |
SOCS1 | NM_003745.1 | −19.48 | 0.014 |
STAT3 | NM_139276.2 | −2.63 | 0.012 |
TANK | NM_004180.2 | −2.38 | 0.042 |
TGFB2 | NM_003238.2 | −4.66 | 0.001 |
Antigen Presentation | |||
CD86 | NM_175862.3 | −14.94 | 0.003 |
HLA-DPA1 | NM_033554.2 | −3.5 | 0.047 |
HLA-DQA1 | NM_002122.3 | −56.6 | 0.020 |
HLA-DQB1 | NM_002123.3 | −23.6 | 0.038 |
HLA-DRA | NM_019111.3 | −4.01 | 0.044 |
MR1 | NM_001531.2 | −2.19 | 0.042 |
Complement | |||
C1R | NM_001733.4 | −4.1 | 0.009 |
C3 | NM_000064.2 | −3.17 | 0.020 |
C7 | NM_000587.2 | 39.95 | 0.025 |
Metabolism | |||
GPI | NM_000175.2 | −2.45 | 0.041 |
HPRT1 | NM_000194.1 | −2.56 | 0.033 |
LGALS3 | NM_001177388.1 | −2.32 | 0.019 |
OAS3 | NM_006187.2 | −9.77 | 0.048 |
Migration and Adhesion | |||
APP | NM_000484.3 | −2.48 | 0.032 |
BST2 | NM_004335.2 | −4.6 | 0.040 |
CD37 | NM_001774.2 | −7.96 | 0.037 |
CD44 | NM_001001392.1 | −2.67 | 0.025 |
CD99 | NM_002414.3 | −3.23 | 0.003 |
CX3CL1 | NM_002996.3 | −2.91 | 0.039 |
CXCL16 | NM_001100812.1 | −2.35 | 0.034 |
CXCR4 | NM_003467.2 | −3.15 | 0.038 |
ITGB4 | NM_001005731.1 | −11.07 | 0.049 |
MUC1 | NM_001018017.1 | −19.27 | 0.018 |
TMUB2 | NM_024107.2 | −3.32 | 0.033 |
VCAM1 | NM_001078.3 | −10.18 | 0.017 |
Phagocytosis | |||
ANXA1 | NM_000700.1 | −5.01 | 0.003 |
CD276 | NM_001024736.1 | −3.01 | 0.023 |
FCGR1A | NM_000566.3 | −8.02 | 0.026 |
LAMP2 | NM_001122606.1 | −2.76 | 0.026 |
Pro-inflammatory Response | |||
CD48 | NM_001778.2 | −7.28 | 0.045 |
CD58 | NM_001779.2 | −4.79 | 0.031 |
CFI | NM_000204.3 | −4.12 | 0.003 |
ELK1 | NM_005229.3 | −2.79 | 0.019 |
IL15RA | NM_002189.2 | −6.88 | 0.046 |
IL6ST | NM_002184.2 | −2.94 | 0.016 |
IRF5 | NM_002200.3 | −6.29 | 0.038 |
LY96 | NM_015364.2 | −21.64 | 0.008 |
MICA | NM_000247.1 | −21.43 | 0.045 |
MYD88 | NM_002468.3 | −2.62 | 0.029 |
NFKB1 | NM_003998.2 | −3.56 | 0.039 |
NFKBIA | NM_020529.1 | −2.24 | 0.023 |
RIPK2 | NM_003821.5 | −3.2 | 0.047 |
TLR3 | NM_003265.2 | −4.91 | 0.007 |
TLR4 | NM_138554.2 | −4.05 | 0.047 |
TLR6 | NM_006068.2 | −2.18 | 0.047 |
TNFRSF10C | NM_003841.3 | −9.92 | 0.039 |
TNFRSF1A | NM_001065.2 | −2.66 | 0.031 |
TNFSF13B | NM_006573.4 | −3.67 | 0.033 |
TNFSF8 | NM_001244.3 | −7.57 | 0.021 |
Survival and Differentiation | |||
BCL10 | NM_003921.2 | −2.09 | 0.033 |
BCL6 | NM_001706.2 | −2.16 | 0.012 |
DUSP6 | NM_001946.2 | −2.75 | 0.031 |
MAP4K2 | NM_004579.2 | −3.16 | 0.048 |
PTPRC | NM_080921.3 | −3.49 | 0.038 |
RORA | NM_134261.2 | −4.41 | 0.014 |
STAT5B | NM_012448.3 | −3.04 | 0.013 |
ZNF346 | NM_012279.2 | −2.64 | 0.012 |
Tissue Modeling and Repair | |||
FOXJ1 | NM_001454.3 | −41.34 | 0.003 |
LRP1 | NM_002332.2 | −2.26 | 0.019 |
PDGFC | NM_016205.2 | −3.72 | 0.024 |
SYT17 | NM_016524.2 | −22.94 | 0.002 |